Cabometyx 60 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DR26FMDX0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $50,367
Award facts
- Contract value 100% obligated
- $50,366.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $50,366.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Cabometyx 60 mg tablets (30-count units). This firm fixed-price delivery order, issued on November 14, 2025, with completion expected by November 17, 2025, carries no set-aside designation, indicating the award was made through unrestricted competition. DMS Pharmaceutical Group, registered in the System for Award Management since 2001, is a critical supplier within the federal pharmaceutical supply chain specializing in distributing branded and generic prescription medications, biologics, vaccines, and medical consumables to Department of Defense healthcare facilities.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated SPE2DR and awarded November 13, 2025, as part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC carries a ceiling value of $499.9 million and extends through December 31, 2036, with a 30-month base period followed by three 30-month option periods. This contract positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, enabling DLA to issue delivery orders for comprehensive pharmaceutical products to support recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FMDX0?
SPE2DR26FMDX0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FMDX0 worth?
The government has obligated $50,367 on SPE2DR26FMDX0.
Is contract SPE2DR26FMDX0 an order under another contract?
Yes. SPE2DR26FMDX0 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDX0 competed?
The extent of competition for SPE2DR26FMDX0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award